Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...
A key gene that fuels the molecular cascade driving prostate cancer bone metastasis progression may open avenues for targeted therapies. With this mda-9 mice model, Fisher and his team observed how ...
This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...
TTUHSC researcher Srinivas Nandana, Ph.D., (left) and co-investigator Manisha Tripathi, Ph.D., received a grant from the U.S. Department of Defense to investigate the role of TBX2 in establishing the ...
Early data show promising results for cabozantinib, a new therapeutic agent for castration-resistant prostate cancer (CRPC), particularly against tumors that have metastasized to the bone. In a phase ...
The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy ...
For more information about Syncromune®, Inc. please visit www.syncromune.com.
An interview with Dr. Philip Saylor from Massachusetts General Hospital on "Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline." This ...
In a study published in the journal Genes & Diseases, researchers from Army Medical University and Shenzhen University investigated the pivotal role of miR-18a-5p, a microRNA, in the development and ...
Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate Traditionally, prostate cancer treatment, as well as all cancer treatment, has been designed to target the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback